Media Release                            

PolyPeptide signs scientific collaboration agreement

Strasbourg, 31 October 2023 – PolyPeptide today announced the signing of a collaboration agreement with the Peptide Sciences Laboratory of the University of KwaZulu-Natal (UKZN) in Durban, South Africa. Professor Fernando Albericio and Professor Beatriz G. de la Torre will support one of PolyPeptide’s innovation projects to improve the sustainability of peptide manufacturing.

Consistent with its strategic aspiration to lead in innovation, PolyPeptide’s global innovation and technology team continues to work on a portfolio of projects to improve the sustainability of peptide manufacturing. This includes efforts to reduce, recycle, replace, or even avoid altogether hazardous solvents, which is particularly relevant against the backdrop of increasing customer demand and growing manufacturing volumes.

PolyPeptide has now signed a collaboration agreement with the University of KwaZulu-Natal (UKZN) in Durban, South Africa, where Fernando Albericio and Beatriz G. de la Torre work as research professors with the Peptide Sciences Laboratory. The purpose of the agreement is to ensure their scientific and academic support for one of PolyPeptide’s innovation projects in solid-phase synthesis. 

Olivier Ludemann-Hombourger, Director Global Innovation and Technology: «With some of our technology projects, we challenge the status quo in peptide manufacturing. If successful, we will be able to significantly increase throughput and productivity, coupled with the optimization of solvent consumption and the reduction of the environmental footprint. At PolyPeptide it is our firm ambition that our customers get their products not only faster but also greener.»

Contact
Michael Stäheli
Head of Investor Relations & Corporate Communications
michael.staeheli@polypeptide.com
T: +41 43 502 0580

About PolyPeptide
PolyPeptide Group AG with its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and services from pre-clinical through to commercial stages, including generics. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Dating back to 1952, PolyPeptide today runs a global network of six cGMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.

@PolyPeptide – follow us on LinkedIn

Cautionary statement on forward-looking information
This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.